ArticleNature communications2024
A light-activatable theranostic combination for ratiometric hypoxia imaging and oxygen-deprived drug activity enhancement.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Coupling photodynamic hypoxia amplification with a self-reporting chemiluminescent prodrug for adaptive precision therapy.Materials today. Bio · 2026Article
- Ultrasound-Activated Nanoinhibitors Blocking the Chemo-Immune Checkpoint to Overcome Chemotherapy-Induced Immune Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Lysosome-Targeted D-π-A Near-Infrared Photosensitizer With Dual Type-I/Type-II ROS Generation for Hypoxia-Resilient Photodynamic Tumor Therapy.Advanced healthcare materials · 2026Article
- Hydroxyl-radical-specific cascade photogeneration for oxygen-chain photocatalytic therapy.Chemical science · 2026Article
- From Spark to Flame: ROS- and Light-Cascade Activatable NIR-II AIE Probe for Precise Tumor Imaging and Self-Amplifying Phototherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy.Polymer science & technology (Washington, D.C.) · 2025Review
- Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors.Acta pharmaceutica Sinica. B · 2025Article
- Granzyme B activated near-infrared-II ratiometric fluorescent nanoprobe for early detection of tumor response to immunotherapy.Nature communications · 2025Article
- Near-infrared II nanomaterials for hypoxic TME diagnosis and therapy.Nanomedicine (London, England) · 2025Review
- Challenging and new opportunities for prodrug technology.Investigational new drugs · 2025Review
- Imaging hypoxia for head and neck cancer: current status, challenges, and prospects.Theranostics · 2025Review
- A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
While performing oxygen-related tumour treatments such as chemotherapy and photodynamic therapy, real-time monitoring hypoxia of tumour is of great value and significance. Here, we design a theranostic combination for light-activated ratiometric hypoxia imaging, hypoxia modulating and prodrug activation. This combination consisted of an oxygen-sensitive near-infrared-emitting ratiometric phosphorescence probe and a hypoxia-activated prodrug-loaded covalent organic framework. In this combination, the probe plays two roles, including quantitative monitoring of oxygen concentration by ratiometric imaging and consuming the oxygen of tumour under light excitation by photodynamic therapy. Meanwhile, the enhanced hypoxia microenvironment of tumour can raise the cytotoxicity of prodrug loaded in covalent organic framework, resulting in boosting antitumour therapeutic effects in vivo. This theranostic combination can precisely provide therapeutic regime and screen hypoxia-activated prodrugs based on real-time tumour hypoxia level, offering a strategy to develop hypoxia mediated tumour theranostics with hypoxia targeted prodrugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.